Incidental identification of small, asymptomatic renal calculi has risen with increasing high-resolution imaging. The natural history of such stones and small residual fragments remains unclear, however kidney stone disease (KSD) demands growing healthcare resource utilisation with wide-ranging costs of treatment and varying management recommendations.
To characterize the general health status of infertile men in the United States using a nationally representative sample of men. Using the National Survey for Family Growth from 2011 to 2017, infertile subgroups were created using a range of inclusion criteria.
We aimed to evaluate the effectiveness and safety of penile plaque incision and buccal mucosa grafting in patients with stable-phase Peyronie’s disease (PD). This was a prospective evaluation of patients with stable-phase PD who were treated by plaque incision and buccal mucosa grafting.
To perform a cost analysis of the current gold standard operation of Holmium Laser Enucleation of the prostate (HoLEP) compared to the new technique of water vapor thermal therapy with the Rezum™ system for the treatment of symptomatic benign prostatic hyperplasia (BPH).
Holmium laser enucleation of the prostate (HoLEP) is a validated alternative to transurethral resection of the prostate (TURP) and open prostatectomy (OP) for surgical treatment of bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH).
{{header-clinical-trials-navigation}} UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer Condition: Metastatic Hormone Naive Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04343885 Sponsor: Peter MacCallum Cancer Centre, Australia Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: […]
Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer.
Background: Stratifying prostate cancer (PCa) patients into risk groups at time of initial diagnosis enabling a risk-adapted disease management is still a major clinical challenge. Existing studies evaluating the prognostic potential of PSMA (prostate-specific membrane antigen) for PCa were performed on radical prostatectomy specimens (RPE), i.
Introduction and Objective Robotic-assisted radical nephrectomy (RRN) is increasingly utilized as an alternative to laparoscopic radical nephrectomy (LRN) but there are concerns over costs and objective benefit.
Immune checkpoint inhibitors (ICI) are an important treatment for metastatic renal cell carcinoma (mRCC). These agents may cause immune-related adverse events (irAEs) and the relationship between irAEs and outcomes is poorly understood.
